TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39134435

Group type: EXPERIMENTAL
Intervention: Maternal microbiome analysis
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Gut microbiome dynamics assessment using 16S and 18S rDNA surveys
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Measurement of maternal weight in first and third trimesters
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Assessment of birth outcomes
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Infant growth and nutritional parameters using WHO z-scores
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Micronutrient analysis in serum using metallomics
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Macronutrient analysis in stool
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Metatranscriptomics and metabolomics
Number of subjects: 400
Study: 39134437

Group type: EXPERIMENTAL
Intervention: Bariatric surgical care journey narrative inquiry
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Patient-Reported Experience Measures and Patient-Reported Outcome Measures
Number of subjects: 16
Study: 39134444

Group type: EXPERIMENTAL
Intervention: Persuasive health communication intervention (PHCI) delivered by video
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Persuasive health communication intervention (PHCI) delivered in person
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current practice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PHCI video with captions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PHCI video without captions
Number of subjects: 0
Study: 39134529

Group type: EXPERIMENTAL
Intervention: Anlotinib plus gefitinib
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Gefitinib plus anlotinib
Number of subjects: 315

Group type: COMPARATOR
Intervention: Gefitinib plus placebo
Number of subjects: 315
Study: 39134652

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for ≤35 cycles with ongoing enzalutamide until progression, unacceptable toxicity, or withdrawal (C4)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for ≤35 cycles with ongoing enzalutamide until progression, unacceptable toxicity, or withdrawal (C5)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for ≤35 cycles with ongoing enzalutamide until progression, unacceptable toxicity, or withdrawal (C4 and C5 combined)
Number of subjects: 126
Study: 39134667

Group type: EXPERIMENTAL
Intervention: Breast milk (2 ml orally)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study: 39134699

Group type: EXPERIMENTAL
Intervention: Oswestry Disability Index (ODI)
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Zürich Claudication Questionnaire (ZCQ)
Number of subjects: 601

Group type: COMPARATOR
Intervention: Global Perceived Effect scale (GPE)
Number of subjects: 601
Study: 39134784

Group type: EXPERIMENTAL
Intervention: ObsQoR-10 at 24 hr postpartum
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: ObsQoR-10 breastfeeding sub-score at 24 hr
Number of subjects: 222
Study: 39134868

Group type: EXPERIMENTAL
Intervention: Online training for 4 weeks followed by telephone counselling for 4 weeks
Number of subjects: 52
Study: 39134959

Group type: COMPARATOR
Intervention: CEM (Carboplatin, Etoposide, Melphalan)
Number of subjects: 58
Study: 39134986

Group type: EXPERIMENTAL
Intervention: Holotranscobalamin (HTC) concentration
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Total vitamin B12 (B12) concentration
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Methylmalonic acid (MMA) concentration
Number of subjects: 99
Study: 39135010

Group type: EXPERIMENTAL
Intervention: CHALLENGE intervention (experimental arm)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Activity monitor-only intervention (comparison arm)
Number of subjects: 300
Study: 39135067

Group type: EXPERIMENTAL
Intervention: Normal brain scan
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Matched with NHDS data
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Matched with NAB data
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Matched with LP biomarker data
Number of subjects: 403
Study: 39135126

Group type: EXPERIMENTAL
Intervention: Minodronate (1 mg/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Alendronate (10 mg/day)
Number of subjects: 72
Study: 39135209

Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal/stem cells (MSCs) therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 20
Study: 39135298

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Empowerment Program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39135452

Group type: EXPERIMENTAL
Intervention: Tofacitinib treatment from baseline to week 18
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Tofacitinib treatment
Number of subjects: 166
Study: 39135540

Group type: EXPERIMENTAL
Intervention: Efzimfotase alfa (15 mg, 45 mg, or 90 mg) administered as one intravenous (i.v.) dose followed by 3 weekly subcutaneous (s.c.) doses.
Number of subjects: 15
Study: 39135926

Group type: EXPERIMENTAL
Intervention: Engagement of trained religious leaders in maternal health education
Number of subjects: 593

Group type: COMPARATOR
Intervention: Regular maternal health information (Control)
Number of subjects: 593
Study: 39136011

Group type: COMPARATOR
Intervention: Zerafil (omalizumab biosimilar) administered at a dose ranging from 150 to 375 mg based on pre-treatment serum total IgE level and body weight every two or four weeks for 28 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omalizumab (reference product) administered at a standard dose.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zerafil (omalizumab biosimilar)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zerafil (omalizumab biosimilar) and Omalizumab (reference product)
Number of subjects: 0
Study: 39136260

Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Daily headache diary
Number of subjects: 40
Study: 39136403

Group type: EXPERIMENTAL
Intervention: Triglyceride-glucose (TyG) index
Number of subjects: 1332
Study: 39136560

Group type: EXPERIMENTAL
Intervention: Selective prostatic arterial administration of gallium 68 PSMA PET/CT radioligand
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous administration of gallium 68 PSMA PET/CT radioligand
Number of subjects: 0
Study: 39136801

Group type: EXPERIMENTAL
Intervention: TransCon PTH treatment
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 19
Study: 39137016

Group type: EXPERIMENTAL
Intervention: Peak Sleep app (3 months of app use)
Number of subjects: 101

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Between-group comparison
Number of subjects: 101
Study: 39137044

Group type: EXPERIMENTAL
Intervention: Teplizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39137100

Group type: EXPERIMENTAL
Intervention: Vivinex XY1 IOL
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clareon CNA0T0 IOL
Number of subjects: 100
Study: 39137167

Group type: EXPERIMENTAL
Intervention: Oral resveratrol (40 mg twice a day for 1 week, then 20 mg twice a day for 6 months)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Matched oral placebo
Number of subjects: 142

Group type: COMPARATOR
Intervention: Comparison of resveratrol vs placebo
Number of subjects: 142
Study: 39137185

Group type: EXPERIMENTAL
Intervention: Self-sampling kits offered to women overdue for cervical cancer screening (CC) during breast cancer screening.
Number of subjects: 27116

Group type: EXPERIMENTAL
Intervention: Self-sampling kits offered to women overdue for colorectal cancer screening (CRC) during breast cancer screening.
Number of subjects: 27116

Group type: EXPERIMENTAL
Intervention: Self-sampling offered to women overdue for CC screening.
Number of subjects: 27116

Group type: EXPERIMENTAL
Intervention: Self-sampling offered to women overdue for CRC screening.
Number of subjects: 27116
Study: 39137205

Group type: EXPERIMENTAL
Intervention: Relative motion (RM) splints
Number of subjects: 36

Group type: COMPARATOR
Intervention: MCPJ blocking splints
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both RM and MCPJ blocking splints
Number of subjects: 36
Study: 39137411

Group type: EXPERIMENTAL
Intervention: RNT-targeting self-help mobile app (MyMoodCoach) used for up to 6 weeks (n=119)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Waitlist control group (usual practice with no access to the app until after 6 weeks, n=117)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: RNT-targeting self-help mobile app (MyMoodCoach)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 236
Study: 39137414

Group type: EXPERIMENTAL
Intervention: FOCUSau (dyadic, psychoeducational intervention adapted for Australian context)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: FOCUSau
Number of subjects: 346
Study: 39137516

Group type: EXPERIMENTAL
Intervention: Saliva osmolality (SOsm)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Serum sodium (Na)
Number of subjects: 38
Study: 39137617

Group type: EXPERIMENTAL
Intervention: In-beam Positron Emission Tomography (PET) monitoring during carbon therapy
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control CT
Number of subjects: 9
Study: 39137624

Group type: EXPERIMENTAL
Intervention: Ketone ester (25 g bis-octanoyl (R)-1,3-butanediol)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (taste, appearance, and calorie-matched containing canola oil)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ketone ester
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 39137977

Group type: EXPERIMENTAL
Intervention: Intermittent Calorie Restriction (iCR)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 39138024

Group type: EXPERIMENTAL
Intervention: Fetal therapy (including thoracoamniotic shunts, antenatal steroids, and combination therapies)
Number of subjects: 435
Study: 39138116

Group type: EXPERIMENTAL
Intervention: Prenatal exome sequencing (pES)
Number of subjects: 56
Study: 39138224

Group type: EXPERIMENTAL
Intervention: Quadrivalent vaccine (QVR)
Number of subjects: 6558

Group type: COMPARATOR
Intervention: Bivalent vaccine (BVR)
Number of subjects: 6558
Study: 39138435

Group type: EXPERIMENTAL
Intervention: Peer support intervention (10-week group course)
Number of subjects: 11
Study: 39138436

Group type: EXPERIMENTAL
Intervention: Erdafitinib 8 mg once daily (with option for up-titration to 9 mg) or 10 mg (7 days on/7 days off for 4 NSCLC patients)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Erdafitinib
Number of subjects: 35
Study: 39138496

Group type: EXPERIMENTAL
Intervention: TEAM-PA intervention
Number of subjects: 54
Study: 39138516

Group type: EXPERIMENTAL
Intervention: Scaffolded games rehabilitation program
Number of subjects: 33

Group type: COMPARATOR
Intervention: Algorithm control of game difficulty
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both interventions (scaffolded games and algorithm control)
Number of subjects: 33
Study: 39138518

Group type: EXPERIMENTAL
Intervention: Trimodulin (human polyvalent immunoglobulin)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Trimodulin
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Trimodulin and Placebo
Number of subjects: 166
Study: 39138537

Group type: EXPERIMENTAL
Intervention: Integrated Care Borderline (ICB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 100
Study: 39138559

Group type: EXPERIMENTAL
Intervention: Land-based aerobic exercise program plus health education
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Water-based aerobic exercise program plus health education
Number of subjects: 48

Group type: COMPARATOR
Intervention: Health education alone (active-control group)
Number of subjects: 48
Study: 39138581

Group type: EXPERIMENTAL
Intervention: PReTEE (simplified three-view TEE protocol)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional TEE
Number of subjects: 46
Study: 39138591

Group type: EXPERIMENTAL
Intervention: Transarterial Chemoembolization (TACE) using doxorubicin and lipiodol
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Genotyping of IL28B and ANGPT2 genes
Number of subjects: 104
Study: 39138719

Group type: EXPERIMENTAL
Intervention: Active PPF-block (5-mL injectates of 20 mg of ropivacaine plus 4 mg of dexamethasone)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo PPF-injection (saline solution)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Active PPF-block
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo PPF-injection
Number of subjects: 195
Study: 39138762

Group type: EXPERIMENTAL
Intervention: Logotherapy counseling program (8 sessions)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 58
Study: 39138826

Group type: EXPERIMENTAL
Intervention: Circulating miR-122-5p, miR-151a-3p, miR-126-5p and miR-21-5p in the MASLD group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of miR-151a-3p or miR-21-5p with leptin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of miR-151a-3p with glucose
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of miR-126-5p with leptin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Circulating miRNAs
Number of subjects: 100
Study: 39138849

Group type: EXPERIMENTAL
Intervention: Presence of OCT-VFs (TCFA, r-MLA, h-PB, CP)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Presence of two or more OCT-VFs
Number of subjects: 429
Study: 39139188

Group type: EXPERIMENTAL
Intervention: SOC-RPM
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: RPM-SOC
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: RPM
Number of subjects: 27
Study: 39139216

Group type: EXPERIMENTAL
Intervention: Ketogenic Diet (KD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ketone Ester
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 0
Study: 39139218

Group type: EXPERIMENTAL
Intervention: Vedolizumab (week 6 serum concentration >41.65 µg/ml)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Vedolizumab (induction and post-induction serum concentrations)
Number of subjects: 436
Study: 39139269

Group type: EXPERIMENTAL
Intervention: Early vitrectomy surgery in addition to antibiotic administration
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravitreal antibiotic administration alone (standard of care)
Number of subjects: 40
Study: 39139270

Group type: EXPERIMENTAL
Intervention: tezacaftor-ivacaftor (TEZ/IVA), 28 days treatment duration
Number of subjects: 13

Group type: COMPARATOR
Intervention: placebo, 28 days treatment duration
Number of subjects: 13
Study: 39139436

Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 2080

Group type: COMPARATOR
Intervention: Contrast Medium
Number of subjects: 2080
Study: 39139457

Group type: EXPERIMENTAL
Intervention: D-penicillamine therapy
Number of subjects: 76
Study: 39140267

Group type: EXPERIMENTAL
Intervention: Unilateral focused ultrasound subthalamotomy (FUS-STN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study: 39140289

Group type: EXPERIMENTAL
Intervention: Safusidenib treatment following biopsy and prior to surgical resection
Number of subjects: 0
Study: 39140490

Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) 5-10 mg
Number of subjects: 1285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1285

Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA)
Number of subjects: 1285

Group type: COMPARATOR
Intervention: Non-OCA patients (external control)
Number of subjects: 1285
Study: 39140573

Group type: EXPERIMENTAL
Intervention: Non-hospitalized patients
Number of subjects: 1198

Group type: COMPARATOR
Intervention: Hospitalized patients
Number of subjects: 1198

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 1198

Group type: EXPERIMENTAL
Intervention: COVID-19 severity variables
Number of subjects: 1198
Study: 39140690

Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 30

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 30
Study: 39140698

Group type: EXPERIMENTAL
Intervention: Group-based pelvic floor muscle training programme
Number of subjects: 48
Study: 39140727

Group type: EXPERIMENTAL
Intervention: Caffeine loading dose
Number of subjects: 56
Study: 39140777

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (DPH) 50 mg
Number of subjects: 20
Study: 39140786

Group type: EXPERIMENTAL
Intervention: Transgender women (with orchiectomy)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Transgender women (without orchiectomy)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reference males
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reference females
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Transgender women (with and without orchiectomy)
Number of subjects: 30
Study: 39140975

Group type: EXPERIMENTAL
Intervention: Paternal obesity (P-OB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (normal paternal BMI)
Number of subjects: 0
Study: 39141364

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 654

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Baricitinib (both doses)
Number of subjects: 654
Study: 39141378

Group type: EXPERIMENTAL
Intervention: Verinurad plus Allopurinol (12 mg plus 300 mg)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Allopurinol (300 mg)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Verinurad plus Allopurinol
Number of subjects: 159

Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 159
Study: 39141379

Group type: EXPERIMENTAL
Intervention: Vergence/accommodative therapy
Number of subjects: 310
Study: 39141382

Group type: EXPERIMENTAL
Intervention: EDTA-based chelation
Number of subjects: 959

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 959
Study: 39141577

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa 1200 mg every 2 weeks (dose-escalation cohort)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa 1200 mg every 2 weeks (dose-expansion cohort)
Number of subjects: 106
Study: 39141622

Group type: EXPERIMENTAL
Intervention: Sleep Restriction Therapy (SRT) delivered over 4 weekly sessions comprising two face-to-face meetings and two telephone calls.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sleep Hygiene Education (SHE) administered in booklet form.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sleep Restriction Therapy (SRT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sleep Hygiene Education (SHE)
Number of subjects: 50
Study: 39141666

Group type: EXPERIMENTAL
Intervention: PC-PTSD-5 screening tool
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: PC-PTSD-5 item 4 (numbing)
Number of subjects: 817
Study: 39141673

Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39141836

Group type: EXPERIMENTAL
Intervention: Absorbable sutures
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Dermabond
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Steri-Strips
Number of subjects: 55

Group type: COMPARATOR
Intervention: Guardian satisfaction with length of stay
Number of subjects: 55

Group type: COMPARATOR
Intervention: Guardian and physician satisfaction with the procedure
Number of subjects: 55

Group type: COMPARATOR
Intervention: Guardian and physician-perceived pain
Number of subjects: 55
Study: 39141853

Group type: EXPERIMENTAL
Intervention: Neuroprosthesis
Number of subjects: 1
Study: 39141854

Group type: EXPERIMENTAL
Intervention: Implanted brain-computer interface for communication
Number of subjects: 1
Study: 39141899

Group type: EXPERIMENTAL
Intervention: Self-guided ICBT with online discussion forum
Number of subjects: 107

Group type: COMPARATOR
Intervention: Self-guided ICBT without online discussion forum
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Both groups (with and without forum)
Number of subjects: 107
Study: 39141987

Group type: EXPERIMENTAL
Intervention: soluble mRNA (100 μg/animal)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: C-terminal transmembrane mRNA (100 μg/animal)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: protein vaccine (400 μg/animal)
Number of subjects: 4

Group type: COMPARATOR
Intervention: non-translatable RNA control (100 μg/animal)
Number of subjects: 4
Study: 39142110

Group type: EXPERIMENTAL
Intervention: Rigorous fluid management using monitoring of ECW ratio by bioelectrical impedance analysis (BIA) with bolus infusion of crystalloid fluid for dehydrated patients and diuretics for overhydrated patients.
Number of subjects: 167

Group type: COMPARATOR
Intervention: Traditional fluid treatment without BIA monitoring.
Number of subjects: 167
Study: 39142511

Group type: EXPERIMENTAL
Intervention: ENDS containing 0 mg/ml liquid nicotine
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: ENDS containing 8 mg/ml liquid nicotine
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: ENDS containing 36 mg/ml liquid nicotine
Number of subjects: 520

Group type: COMPARATOR
Intervention: Cigarette-shaped plastic tube (control)
Number of subjects: 520
Study: 39142675

Group type: EXPERIMENTAL
Intervention: Clinical pathway intervention for pelvic fragility fractures
Number of subjects: 393

Group type: COMPARATOR
Intervention: Current practice (control group)
Number of subjects: 393
Study: 39142677

Group type: EXPERIMENTAL
Intervention: Carbohydrate-reduced high-protein (CRHP) diet
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional diabetes (CD) diet
Number of subjects: 100
Study: 39142680

Group type: EXPERIMENTAL
Intervention: Upfront dose-reduced chemotherapy (25% reduction)
Number of subjects: 587

Group type: COMPARATOR
Intervention: Full-dose chemotherapy (fluoropyrimidine plus oxaliplatin)
Number of subjects: 587

Group type: COMPARATOR
Intervention: Fluoropyrimidine monotherapy (full-dose)
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Dose-reduced chemotherapy (25% reduction)
Number of subjects: 587